Leuprolide with and without flutamide in advanced prostate cancer.

摘要: In a randomized, double-blind trial for metastatic prostate cancer (Stage D2), 603 men received leuprolide, gonadotropin-releasing hormone analog that inhibits the release of gonadotropins, coupled with either placebo or flutamide, nonsteroidal antiandrogen binding androgens to cell nucleus. The 303 receiving androgen blockade leuprolide and flutamide demonstrated longer progression-free survival (16.9 vs. 13.9 months, P = 0.039) an increased median length (35.0 27.9 0.035). subgroup minimal disease good performance status, advantages maximal were more pronounced. It is concluded combined was effective than alone patients prostate. therapeutic benefits, although greatest in minimum disease, need be evaluated prospective, randomized fashion trials specifically designed status. Exploratory analyses using black race as explanatory variable also performed. Black associated shorter times other prognostic factors, including recent weight loss, anemia, elevated phosphatase levels, pain. These findings suggest future studies relationship response therapy.